Current Opinion in Hematology volume 19, issue 2, P117-123 2012 DOI: 10.1097/moh.0b013e32834ff575 View full text
|
|
Share
Francesco Passamonti, Margherita Maffioli, Domenica Caramazza

Abstract: Patients who might benefit from JAK2 inhibitors in clinical practice are mostly those with splenomegaly or with constitutional symptoms. We should alert patients with lower hemoglobin levels that these therapies might, although temporarily, favor the need for red blood cell transfusions.